Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phillygenin is a natural lignan monomer isolated from the fruit of *Forsythia suspensa* (Lianqiao). It exhibits a wide range of pharmacological activities, including anti-inflammatory, antioxidant, hepatoprotective, and anticancer properties. Phillygenin acts as a direct agonist of the G-protein coupled bile acid receptor 1 (GPBAR1/TGR5) and an inhibitor of maternal embryonic leucine zipper kinase (MELK) and Toll-like receptor 4 (TLR4). It has been shown to activate AMP-activated protein kinase (AMPK) and suppress downstream inflammatory pathways, including the TLR4/MyD88/NF-κB and NLRP3 inflammasome cascades. Phillygenin is being investigated preclinically for the treatment of various conditions, including sepsis-associated acute kidney injury (SA-AKI), diabetic nephropathy, ulcerative colitis, severe acute pancreatitis, arthritis, neuropathic pain, pancreatic cancer, and hepatocellular carcinoma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phillygenin.